Financials data is unavailable for this security.
View more
Year on year NextCell Pharma AB had net income fall 15.21% from a loss of 34.55m to a larger loss of 39.81m despite a 80.96% increase in revenues from 5.59m to 10.11m.
Gross margin | -193.25% |
---|---|
Net profit margin | -314.54% |
Operating margin | -325.09% |
Return on assets | -47.56% |
---|---|
Return on equity | -56.78% |
Return on investment | -54.11% |
More ▼
Cash flow in SEKView more
In 2023, cash reserves at NextCell Pharma AB fell by 47.09m. Cash Flow from Financing totalled 835.66k or 8.26% of revenues. In addition the company used 43.83m for operations while cash used for investing totalled 4.10m.
Cash flow per share | -0.8464 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.08 |
---|---|
Tangible book value per share | 1.08 |
More ▼
Balance sheet in SEKView more
Current ratio | 3.83 |
---|---|
Quick ratio | 3.75 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼